Company news

Prescient Therapeutics Limited news in 2025

Prescient Therapeutics Limited's news releases, calls and decks from 2025, newest first.

View company

PTX secures EU Authorisation to commence PTX-100 Trial

December 14, 2025

PTX secures EU Orphan Drug Designation for PTX-100 in CTCL

November 18, 2025

September Quarterly Updated and Appendix 4C

October 9, 2025

Appendix 4E and 2025 Annual Report

August 20, 2025

Prescient successfully completes $3 million Placement

July 31, 2025

June 2025 Quarterly Update and Appendix 4C

July 30, 2025

Prescient announces results of SPP & Launches Placement

July 29, 2025

Trading Halt

July 28, 2025

Prescient Therapeutics - Extension of Share Purchase Plan

July 22, 2025

PTX Opens First U.S. Site for PTX-100 Phase 2a Trial

July 15, 2025

Prescient Therapeutics Extends Share Purchase Plan

July 14, 2025

Prescient Therapeutics Opens Share Purchase Plan

July 1, 2025

Prescient Therapeutics Launches Share Purchase Plan for $7m

June 30, 2025

First Patient dosed for PTX-100 Phase 2a Study

May 26, 2025

March 2025 Quarterly Update and Appendix 4C

April 28, 2025

PTX-100 receives U.S. FDA Fast Track Designation

April 15, 2025

PTX Opens First Clinical site for PTX-100 Phase 2a Study

March 25, 2025

December 2024 Quarterly Update and Appendix 4C - amended

January 31, 2025

December 2024 Quarterly Update and Appendix 4C

January 30, 2025

Decks in 2025